ProMIS Neurosciences 미래 성장

Future 기준 확인 0/6

ProMIS Neurosciences의 수익이 증가할 것으로 예상됨입니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Biotechs 수익 성장	28.3%
매출 성장률	84.6%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	14 Nov 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

NasdaqCM:PMN - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	N/A	N/A	N/A	N/A	2
12/31/2025	N/A	N/A	N/A	N/A	2
12/31/2024	N/A	N/A	N/A	N/A	2
9/30/2024	N/A	-1	-22	-22	N/A
6/30/2024	N/A	-12	-18	-18	N/A
3/31/2024	N/A	-12	-19	-19	N/A
12/31/2023	N/A	-13	-11	-11	N/A
9/30/2023	N/A	-17	-12	-12	N/A
6/30/2023	N/A	-20	-14	-14	N/A
3/31/2023	N/A	-21	-16	-16	N/A
12/31/2022	N/A	-18	-17	-17	N/A
9/30/2022	N/A	-13	-17	-17	N/A
6/30/2022	N/A	-8	-15	-15	N/A
3/31/2022	N/A	-6	-12	-12	N/A
12/31/2021	N/A	-10	-9	-9	N/A
9/30/2021	N/A	-8	-6	-6	N/A
6/30/2021	N/A	-8	-4	-4	N/A
3/31/2021	0	-9	-3	-3	N/A
12/31/2020	0	-4	-4	-3	N/A
9/30/2020	0	-5	-4	-4	N/A
6/30/2020	0	-5	-4	-4	N/A
3/31/2020	0	-5	-4	-4	N/A
12/31/2019	0	-6	-5	-5	N/A
9/30/2019	0	-7	-6	-6	N/A
6/30/2019	0	-8	-7	-7	N/A
3/31/2019	0	-8	-7	-7	N/A
12/31/2018	0	-7	-6	-6	N/A
9/30/2018	0	-6	-6	-6	N/A
6/30/2018	0	-5	N/A	-5	N/A
3/31/2018	0	-5	N/A	-5	N/A
12/31/2017	0	-5	N/A	-5	N/A
9/30/2017	0	-5	N/A	-4	N/A
6/30/2017	0	-4	N/A	-3	N/A
3/31/2017	0	-3	N/A	-3	N/A
12/31/2016	0	-3	N/A	-2	N/A
9/30/2016	0	-2	N/A	-2	N/A
6/30/2016	0	-2	N/A	-2	N/A
3/31/2016	0	-2	N/A	-2	N/A
12/31/2015	0	-2	N/A	-1	N/A
9/30/2015	0	-1	N/A	-1	N/A
6/30/2015	0	-2	N/A	-1	N/A
3/31/2015	0	-2	N/A	-1	N/A
12/31/2014	0	-2	N/A	-2	N/A
9/30/2014	0	-3	N/A	-2	N/A
6/30/2014	0	-2	N/A	-2	N/A
3/31/2014	0	-2	N/A	-2	N/A
12/31/2013	0	-2	N/A	-1	N/A

애널리스트 미래 성장 예측

수입 대 저축률: PMN 의 예상 수익 증가율이 절약률( 2.6% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: PMN 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: PMN 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: PMN 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: PMN 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: PMN 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

ProMIS Neurosciences 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Recent updates

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

ProMIS Neurosciences, Inc. Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

ProMIS Neurosciences, Inc. announced that it expects to receive CAD 30.3 million in funding from Great Point Partners, LLC, Armistice Capital LLC, Ally Bridge Group, Sphera Funds Management Ltd and other investors

ProMIS Neurosciences, Inc. Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Receives Written Notice from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5550(b)(2)

ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease

ProMIS Neurosciences to Delist from TSX

ProMIS Neurosciences Inc. Announces FDA Clearance of Investigational New Drug Application for PMN310 in Alzheimer’s Disease

ProMIS Neurosciences, Inc. announced that it has received $7.472277 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. to Present At 2022 Alzheimer's Association International Conference

ProMIS Neurosciences Common Shares Deleted from Other OTC

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Pmn310 Antibody Demonstrates Significant Cognitive Benefit in A Mouse Model of Alzheimer’s Disease

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences, Inc. Initiates Program to Develop Monoclonal Antibodies to Treat Schizophrenia and Other Chronic Mental Illnesses

ProMIS Neurosciences, Inc. has completed a Composite Units Offering in the amount of $17.5 million.

ProMIS Neurosciences, Inc. Initiates Commercialization of Covid-19 Serology Assay

ProMIS Neurosciences Re-Initiates Path to IND for PMM310 with Producer Cell Line Development

ProMIS Neurosciences, Inc. announced that it has received CAD 8.75 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences, Inc. Announces Perspectives on Recent Progress in the Alzheimer's Field

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

ProMIS Neurosciences, Inc. Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

ProMIS Neurosciences, Inc. Announces Resignation of Anthony Giovinazzo from the Board of Directors

ProMIS Neurosciences, Inc. to Develop Multivalent Vaccine for Alzheimer’s Disease

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견